Pacira BioSciences Quarterly Cash Flow Statement
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pacira BioSciences free cash flow
In the quarter ended Jun 30, 2026, Pacira BioSciences generated $57.5 million of operating cash flow and spent $1.3 million on capital expenditures. That left free cash flow of $56.1 million, a free-cash-flow margin of 29.2% of revenue. Free cash flow was up 502.5% from the prior year's $9.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Pacira BioSciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.65M | 2.92M | 1.64M | 5.43M | -4.85M | 4.81M | 16.04M | -143.47M | 18.89M | 8.98M | 24.87M | 10.86M |
| Net Income growth (YoY) | — | -39.40% | -89.79% | — | -125.66% | -46.41% | -35.50% | -1421.29% | -26.69% | — | — | — |
| Depreciation & Amortization | 21.30M | 21.33M | 21.34M | 21.19M | 27.32M | 21.17M | 21.24M | 20.25M | 18.86M | 18.43M | 18.48M | 18.43M |
| Stock-Based Compensation | 14.96M | 13.54M | 13.50M | 13.98M | 15.47M | 14.55M | 12.27M | 13.23M | 12.52M | 13.15M | 12.42M | 12.53M |
| Change in Working Capital | 4.62M | -1.26M | 5.79M | -26.78M | -17.48M | -1.57M | -16.09M | -9.10M | -2.27M | 4.64M | -15.19M | -12.82M |
| Operating Cash Flow | 57.46M | 25.68M | 43.69M | 60.83M | 12.01M | 35.46M | 33.13M | 53.92M | 53.24M | 49.10M | 47.58M | 44.44M |
| Capital Expenditures | -1.34M | -2.72M | -218.00K | -3.87M | -2.70M | -8.55M | -2.12M | -4.09M | -1.59M | -2.84M | -1.80M | -3.39M |
| Investing Cash Flow | 11.76M | 19.44M | 19.33M | 43.61M | 62.16M | -25.63M | -368.00K | -52.16M | -15.21M | -15.53M | 8.37M | -4.34M |
| Share Repurchases | 0 | -50.05M | -48.25M | -50.04M | -50.04M | 0 | 0 | 0 | — | — | 0 | 0 |
| Financing Cash Flow | -7.65M | -59.40M | -51.65M | -257.48M | -57.51M | -2.99M | -1.96M | -2.85M | 24.98M | -2.82M | -1.78M | -27.79M |
| Net Change in Cash | 61.57M | -14.24M | 10.96M | -152.90M | 16.87M | 6.84M | 30.81M | -1.09M | 63.00M | 30.75M | 54.18M | 12.31M |
| Free Cash Flow | 56.12M | 22.96M | 43.47M | 56.96M | 9.31M | 26.91M | 31.01M | 49.83M | 51.65M | 46.27M | 45.79M | 41.04M |
This table shows 12 quarterly periods of Pacira BioSciences's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PCRX's reporting calendar. What is a cash flow statement?